| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| PRE 14A | A preliminary proxy statement providing notification matters to be brought to a vote |
Proxy Filings
|
||
| PREC14A | Preliminary proxy statement containing contested solicitations |
Proxy Filings
|
||
| PREC14A | Preliminary proxy statement containing contested solicitations |
Proxy Filings
|
||
| PREM14A | A preliminary proxy statement relating to a merger or acquisition |
Mergers & Acquisitions
|
||
| PRER14A | Proxy soliciting materials. Revised preliminary material |
Proxy Filings
|
||
| PRER14A | Proxy soliciting materials. Revised preliminary material |
Proxy Filings
|
||
| PRER14A | Proxy soliciting materials. Revised preliminary material |
Proxy Filings
|
||
| PRRN14A | Non-management revised preliminary proxy soliciting materials |
Proxy Filings
|
||
| PRRN14A | Non-management revised preliminary proxy soliciting materials |
Proxy Filings
|
||
| PRRN14A | Non-management revised preliminary proxy soliciting materials |
Proxy Filings
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
